

MATERIALS LICENSE


Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 02120

315347

<p>Licensee</p> <p>1. Midwest Division - MCI, LLC (d/b/a Medical Center of Independence)</p> <p>2. 17203 E. 23rd Street Independence, MO 64057</p>	<p>In accordance with the letter dated March 23, 2006,</p> <p>3. License number 24-18818-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date March 31, 2011</p> <hr/> <p>5. Docket No. 030-14213 Reference No.</p>
--	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200 (excluding xenon-133)</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any (excluding generators)</p> <p>C. Any</p> <p>D. Sealed sources (Theragance Corp. Model 200; Medi-Physics Model 7000 RAPID Strand and 6711 Oncoseed)</p> <p>E. Prepackaged Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p> <p>D. 500 millicuries</p> <p>E. As needed</p>
---	--	--



9. **Authorized Use:**
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200 (excluding xenon-133 and generators).
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 - E. In vitro studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-18818-01

Docket or Reference Number
030-14213

Amendment No. 25

CONDITIONS

10. Location of Use: 17203 E. 23rd Street, Independence, MO 64057.

11. Radiation Safety Officer: Robert F. Thompson, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for for the materials and uses indicated:

Authorized Users

Material and Use

Richard A. Morrison, M.D.

10 CFR 35.400.

Alan Schneider, M.D.

10 CFR 35.100, and 35.200 (limited to cardiovascular clinical studies).

Stephen A. Bloom, M.D.

10 CFR 35.100 and 35.200 (limited to cardiovascular clinical studies).

David E. Hazuka, M.D.

10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.

Stephen R. Kunz, M.D.

10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.

Gwendolyn Ramsey Arnett, M.D.

10 CFR 35.100, 35.200, 35.300 and 31.11.

Robert F. Thompson, M.D.

10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.

Dipak Shah, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to iodine-131, strontium-89 and samarium-153) and 31.11.

Richard L. Cronemeyer, M.D.

10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.

Mark J. Lavin, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

William G. Jensen, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-18818-01

Docket or Reference Number
030-14213

Amendment No. 25

Kenneth M. Alfieri, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Joseph J. Varriano, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Matthew R. Caterine, M.D.	10 CFR 35.100, 35.200 and 31.11.
Maynard C. Jones, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding thyroid carcinoma) and 31.11.
Michael Malis, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.
David Mena, M.D.	10 CFR 35.100, 35.200 and 31.11
Michael N. Roys, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 31.11.


13. In addition to the possession limits in Condition 8, the licensee shall further restrict the possession of licensed material to quantities below the limits specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Notwithstanding the provisions of Section 35.49(a) of Title 10, Code of Federal Regulations, the licensee is authorized to receive sealed brachytherapy sources listed in Section 35.400 from NRC License Number 24-19486-02 issued to Richard A. Morrison, M.D., in accordance with the procedures outlined in application dated November 17, 2000.
15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-18818-01Docket or Reference Number
030-14213

Amendment No. 25

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated November 17, 2000 (~~excluding~~ the Quality Management Program); and
- B. Letters dated March 26, 2003 and April 15, 2003 (with enclosure).



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAY 22 2006 By Toye L. Simmons
Toye L. Simmons
Materials Licensing Branch
Region III